Can a precision drug outsmart hard-to-treat colorectal cancer?

NCT ID NCT07730489

First seen Jul 28, 2026 · Last updated Jul 29, 2026 · Updated 1 time

Summary

This phase III trial is testing whether an experimental drug called BL-M07D1 can slow or stop the growth of advanced colorectal cancer in people whose tumors have high levels of the HER2 protein and who have already tried standard chemotherapy. Participants will be randomly assigned to receive either BL-M07D1 or one of several standard treatments chosen by their doctor. The study aims to see if the new drug improves how long people live without their cancer worsening.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
an experimental antibody-drug conjugate called BL-M07D1
What this could lead to
If successful, this could offer a new targeted treatment option for people with HER2-positive advanced colorectal cancer who have run out of standard options.
What could go wrong
This is an early-phase trial with a relatively small number of participants, and the experimental drug may not prove more effective or safer than existing therapies. Side effects from the drug are also possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • The First Hospital of China Medical University

    Shenyang, Liaoning, China

  • ZhongShan Hospital Fudan University

    Shanghai, Shanghai Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.